Biofrontera Q3 Revenue Jumps 30% to $9.1M on Ameluz Growth

Biofrontera Inc. (NASDAQ: BFRI) reported third-quarter 2026 net product revenue of $9.1 million on November 13, 2026, a 29.8% increase from $7.0 million in the same quarter a year earlier, according to the company's earnings release. Gross margin expanded to 74.4% from 70.7%, while net loss narrowed to $6.4 million, or $(0.42) per share, from $6.6 million, or $(0.62) per share. Adjusted EBITDA improved to $(5.5) million from $(6.0) million. The quarter followed FDA approval of Ameluz PDT for superficial basal cell carcinoma on September 9, 2026.

Context — Why Biofrontera's Third Quarter Matters Now

The company said the September 9 FDA approval made Ameluz plus red-light the first and only photodynamic therapy cleared in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that Biofrontera's redesigned RhodoLED XL-C lamp was not subject to the U.S. International Trade Commission exclusion order tied to the earlier XL lamp. That order had taken effect July 6, 2026.

Those two events reset the commercial picture. The ITC Matter had restricted the company's ability to supply the large-field lamp that dermatology practices use alongside Ameluz. Without the lamp, the drug's addressable base was constrained.

Biofrontera's margin story also traces to an October 2025 strategic transaction with Biofrontera AG. The company said the deal replaced its prior transfer pricing arrangement with a cost structure of Ameluz direct cost plus a 12% earnout on net revenue. That shift lowered the cost of the drug even as unit volume rose 23.3% year over year in the quarter.

The backdrop for small-cap biopharma remains rate-sensitive, with financing costs still elevated relative to the low-rate era. Biofrontera ended the quarter with $3.2 million in cash and cash equivalents, down from $6.4 million at December 31, 2025, and no bank or other term debt beyond $4.7 million of convertible notes due November 2027.

Data — What Biofrontera's Numbers Show

Third-quarter net product revenue rose $2.1 million, or 29.8%, to $9.1 million. The company attributed $1.6 million of that to a 23.3% increase in Ameluz unit volume, $0.3 million to price and mix, and the balance to higher device sales. Management said accelerated ordering from certain customers in early July 2026, ahead of potential supply restrictions from the ITC order, contributed to the volume gain, though it characterized the effect as timing rather than incremental demand.

Metric	Q3 2026	Q3 2025	Change
Net product revenue	$9.1M	$7.0M	+29.8%
Gross margin	74.4%	70.7%	+370 bps
Net loss	$6.4M	$6.6M	Narrowed
Loss per share	$(0.42)	$(0.62)	Narrowed
Adjusted EBITDA	$(5.5)M	$(6.0)M	Improved

For the nine months ended September 30, 2026, net product revenue was $31.2 million, up 26.6% from $24.6 million. Gross margin for the period was 78.0% versus 67.7%. Net loss narrowed to $11.8 million, or $(0.89) per share, from $16.2 million, or $(1.67) per share. Adjusted EBITDA improved to $(9.3) million from $(15.5) million.

Operating cash use fell to $3.2 million for the nine months, against $11.0 million in the prior-year period. SG&A, including related-party SG&A, rose to $12.5 million in the quarter from $10.4 million, with $0.9 million of that tied to ITC Matter legal fees.

Analysis — What It Means for Markets and Sectors

Biofrontera sits in a narrow slice of dermatology: photodynamic therapy, where the drug and the light source are sold together. The XL-C clearance matters because it restores the company's ability to serve accounts that had been unable to buy Ameluz while the lamp was excluded. The company said it began placing XL-C lamps during the third quarter.

The sBCC label is the larger strategic swing. Basal cell carcinoma is the most common form of skin cancer, and Biofrontera's pitch is that its existing lamps and sales force already reach the dermatologists who treat it. Management said it is preparing to begin commercializing Ameluz for sBCC later in the fourth quarter and into the first quarter of 2027. In October, the company submitted a supplemental New Drug Application to expand the Ameluz label for actinic keratosis to the extremities, neck and trunk.

The counter-argument is cost. The quarter carried $0.3 million of patent remediation expense and $0.3 million of ITC Matter-related inventory write-downs inside cost of revenues. Through September 30, total ITC Matter charges reached $1.1 million. SG&A is growing faster than revenue in dollar terms, and the company is still burning cash, which keeps financing risk on the table for a name with a $3.2 million cash balance.

Positioning in small-cap biopharma like this tends to be event-driven. The approval and the customs ruling removed two overhangs, but the next leg depends on whether sBCC adoption shows up in prescriptions rather than in guidance.

Outlook — What to Watch Next

Biofrontera said it expects to begin commercializing Ameluz for sBCC late in the fourth quarter of 2026 and into the first quarter of 2027. The supplemental NDA for actinic keratosis on the extremities, neck and trunk, submitted in October 2026, is the next regulatory checkpoint, though the company did not disclose a review timeline.

The convertible notes mature in November 2027, and the company ended the quarter with $3.2 million in cash. Any update on liquidity or additional financing is the variable most likely to move the shares. The company did not disclose sBCC revenue expectations or a timeline for XL-C placement completion.

Investors scanning the healthcare sector should watch the fourth-quarter report for evidence that sBCC revenue is incremental rather than pulled forward from the existing actinic keratosis base. The equities tape for small-cap biopharma remains sensitive to rate expectations, which the company does not control.

Frequently Asked Questions

What does the FDA approval of Ameluz for sBCC mean for Biofrontera?

The September 9, 2026 approval makes Ameluz plus red-light the first PDT cleared in the U.S. for a cancerous skin tumor, per the company. Biofrontera said it plans to commercialize the indication using lamps and a sales force already in place, starting late in the fourth quarter of 2026 and into the first quarter of 2027. The company has not disclosed revenue expectations for the new label.

Why did Biofrontera's gross margin improve in Q3 2026?

The company said the improvement to 74.4% from 70.7% reflects the lower Ameluz cost structure established after the October 2025 strategic transaction with Biofrontera AG, which replaced prior transfer pricing with direct cost plus a 12% earnout on net revenue. That was partly offset by $0.4 million of higher lamp and device costs, including $0.3 million of ITC Matter-related inventory write-downs.

What is the ITC Matter and how much has it cost Biofrontera?

The ITC Matter refers to the U.S. International Trade Commission's limited exclusion order and cease and desist order on the RhodoLED XL lamp, effective July 6, 2026. On September 14, 2026, U.S. Customs and Border Protection ruled the redesigned XL-C was not subject to the order. The company said total ITC Matter charges reached $1.1 million through September 30, 2026.

Bottom Line

Biofrontera's 30% quarterly revenue growth and wider margin now hinge on converting the new sBCC approval into prescriptions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.